Research Analysts Issue Forecasts for Deciphera Pharmaceuticals, Inc.’s Q1 2022 Earnings (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) – Equities researchers at SVB Leerink raised their Q1 2022 earnings per share (EPS) estimates for Deciphera Pharmaceuticals in a report issued on Thursday, April 28th. SVB Leerink analyst A. Berens now forecasts that the company will post earnings of ($0.90) per share for the quarter, up from their prior forecast of ($0.96). SVB Leerink also issued estimates for Deciphera Pharmaceuticals’ Q2 2022 earnings at ($0.63) EPS, Q3 2022 earnings at ($0.57) EPS, Q4 2022 earnings at ($0.51) EPS, FY2022 earnings at ($2.55) EPS, FY2023 earnings at ($2.52) EPS, FY2024 earnings at ($2.10) EPS, FY2025 earnings at ($0.55) EPS and FY2026 earnings at $1.61 EPS.

Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Rating) last issued its quarterly earnings results on Tuesday, February 8th. The company reported ($1.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.02). The firm had revenue of $24.20 million for the quarter, compared to analyst estimates of $23.28 million. Deciphera Pharmaceuticals had a negative return on equity of 72.17% and a negative net margin of 306.78%. The company’s revenue was up 24.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.10) earnings per share.

Separately, Barclays cut Deciphera Pharmaceuticals from an “equal weight” rating to an “underweight” rating and reduced their price target for the company from $11.00 to $6.00 in a report on Monday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $23.11.

NASDAQ DCPH opened at $10.12 on Monday. The stock’s 50 day simple moving average is $9.14. Deciphera Pharmaceuticals has a 12-month low of $6.51 and a 12-month high of $11.85. The firm has a market cap of $592.55 million, a PE ratio of -1.97 and a beta of 1.59.

A number of institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System boosted its stake in shares of Deciphera Pharmaceuticals by 2.2% during the 4th quarter. California State Teachers Retirement System now owns 55,595 shares of the company’s stock worth $543,000 after purchasing an additional 1,187 shares during the last quarter. Point72 Hong Kong Ltd acquired a new stake in Deciphera Pharmaceuticals during the third quarter worth approximately $53,000. Bank of America Corp DE grew its stake in Deciphera Pharmaceuticals by 11.5% in the 2nd quarter. Bank of America Corp DE now owns 17,682 shares of the company’s stock worth $647,000 after acquiring an additional 1,828 shares during the period. Denali Advisors LLC raised its holdings in Deciphera Pharmaceuticals by 33.9% in the 1st quarter. Denali Advisors LLC now owns 7,900 shares of the company’s stock valued at $73,000 after acquiring an additional 2,000 shares during the last quarter. Finally, Credit Suisse AG lifted its stake in shares of Deciphera Pharmaceuticals by 7.3% during the 3rd quarter. Credit Suisse AG now owns 34,571 shares of the company’s stock worth $1,176,000 after purchasing an additional 2,353 shares during the period. 91.37% of the stock is owned by institutional investors.

In other news, major shareholder Brightstar Associates Llc purchased 1,478,978 shares of the company’s stock in a transaction dated Friday, April 29th. The stock was acquired at an average price of $10.00 per share, for a total transaction of $14,789,780.00. Following the completion of the transaction, the insider now directly owns 18,051,348 shares in the company, valued at approximately $180,513,480. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold a total of 3,718 shares of company stock valued at $33,648 over the last ninety days. 4.10% of the stock is currently owned by company insiders.

About Deciphera Pharmaceuticals (Get Rating)

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.

Featured Stories